Inhaled fluticasone propionate. A review of its therapeutic efficacy at dosages ≤ 500 μg/day in adults and adolescents with mild to moderate asthma

Drugs

Volumn 57, Issue 5, 1999, Pages 769-803

  Jarvis, Blair ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; FLUNISOLIDE; FLUTICASONE PROPIONATE; NEDOCROMIL; SALMETEROL; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE; ZAFIRLUKAST;

ASTHMA; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MAINTENANCE THERAPY; META ANALYSIS; QUALITY OF LIFE; RECEPTOR AFFINITY; REVIEW; SPIROMETRY; SYMPTOM; THRUSH;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS;

EID: 0032898446     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957050-00016     Document Type: Review

References (124)

1. Legorreta AP, Christian-Herman J, O'Connor RD, et al. Compliance with national asthma management guidelines and specialty care. A health maintenance organization experience. Arch Intern Med 1998; 158: 457-64
2. Lange P, Ulrik CS, Vestbo J, et al. Mortality in adults with self-reported asthma. Lancet 1996; 347: 1285-9
3. Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194-200
4. Barnes PJ. Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. J Allergy Clin Immunol 1098; 101 (4 Pt 2): S427-33
5. Meijer RJ, Kerstjens HAM, Postma DS. Comparison of guidelines and self-management plans in asthma. Eur Respir J 1997; 10: 1163-72
6. National Heart Lung and Blood Institute. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. National Institutes of Health. National Heart, Lung, and Blood Institute. 1995 Jan; Publicalion Number 95-3659
7. British Thoracic Society. The British guidelines on asthma management 1995 review and position statement. Thorax 1997 Feb; 52 Suppl. 1: S1-21
8. National Asthma Education and Prevention Program. Expert Panel report II: guidelines for the diagnosis and management of asthma. Bethesda: National Heart, Lung, and Blood Institute Information Center. 1997 Feb.
9. Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs 1994 Feb; 47: 318-31
10. Rahman SU, Rhodes CG, Ind PW, et al. Effect of corticosteroids on pulmonary β adrenergic receptor density and function [abstract no. P1103]. Eur Respir J 1998; 12 Suppl. 28: 156s
11. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995 Mar 30; 332: 868-75
12. Olivieri D, Chetta A, Del Donno M, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997 Jun; 155: 1864-71
13. Bertorelli G, Bocchino V, Zhuo X, et al. Heat shock protein 70 upregulation is related to HLA-DR expression in bronchial asthma. Effects of inhaled glucocorticoids. Clin Exp Allergy 1998; 28: 551-60
14. Noonan MJ, Chervinsky P, Wolfe J, et al. Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind placebo-controlled study. J Asthma 1998; 35: 153-64
15. Westbrock J, Pasma HR. The effect of inhaled fluticasone propionate (FP) 100 μg bd compared with oral zafirlukast 20 mg bd on bronchial hyperresponsiveness in mild to moderate asthma. Eur Respir J 1997 Sep; (10 Suppl. 25): 243s
16. Weersink EJM, Douma RR, Postma DS. Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Am J Respir Crit Care Med 1997 Apr; 155: 1241-6
17. Lipworth BJ. Airway and systematic effects of inhaled corticosteroids in asthma: dose response relationship. Pulmon Pharmacol 1996 Feb; 9: 19-27
18. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52: 476-82
19. Chervinsky P, van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994 Oct; 94: 676-83
20. Lawrence M, Wolfe J, Webb DR, et al. Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am J Respir Crit Care Med 1997 Sep; 156 (Pt 1): 744-51
21. Wasserman SI, Gross GN, Schoenwetter WF, et al. A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. J Asthma 1996; 33 (4): 265-74
22. Pearlman DS, Noonan MJ, Tashkin DP, et al. Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Ann Allergy Asthma Immunol 1997 Apr; 78: 356-62
23. Kellerman D, Stricker W, Howland W, et al. Effects of inhaled fluticasone propionate (FP) on the HPA axis of patients with asthma [abstract]. Eur Respir J 1996 Sep; 9 Suppl. 23: 162s
24. Harding SM, Herje NE, Hamedani AG. Comparison of the long-term effects of inhaled fluticasone propionate (FP) on the HPA axis in patients with asthma [abstract]. Ann Allergy Asthma Immunol 1997 Jan; 78: 156
25. Dahl R, Lundback B, Malo JL, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest 1993 Nov; 104: 1352-8
26. Derom E, Van Schoor J, Vincken W, et al. A comparison of the systemic activity of 2 doses of inhaled fluticasone propionate and budesonide in asthmatic patients [abstract]. American Lung Association/American Thoracic Society 1997 International Conference, San Francisco, CA 1997 May 16-21: 41
27. Connolly A, UK Study Group. A comparison of fluticasone propionate 100 μg twice daily with budesonide 200 μg twice daily via their respective powder devices in the treatment of mild asthma. Eur J Clin Res 1995; 7: 15-29
28. Langdon CG, Capsey LJ, UK Study Group. Fluticasone propionate and budesonide in adult asthmatics: a comparison using dry-powder inhaler devices. Br J Clin Res 1994; 5: 85-99
29. Langdon CG, Thompson J, Uk SG, et al. A multicentre study to compare the efficacy and safety of inhaled fluticasone propionate and budesonide via metered-dose inhalers in adults with mild-to-moderate asthma. Br J Clin Res 1994; 5: 73-84
30. Grahnen A, Brundin RM, Ling-Andersson A, et al. Systemic potency of fluticasone propionate vs budesonide, from dry powder inhalers [abstract no. P1071]. Eur Respir J 1996; 9 Suppl. 23: 164s
31. Wilson AM, Clark DJ, Devlin MM, et al. Adrenocortical activity with repeated administration of once-daily inhaled fluticasone propionate and budesonide in asthmatic adults. Eur J Clin Pharmacol 1998; 53: 317-20
32. Wilson AM, McFarlane LC, Lipworth BJ. Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics. Am J Respir Crit Care Med 1997 Oct; 156 (Pt 1): 1274-7
33. Storms W, Howland WC, Sorkness CA, et al. Fluticasone propionate (FP), triamcinolone acetonide (TAA) and flunisolide (FLN) have similar effects on the HPA axis [abstract]. J Allergy Clin Immunol 1997 Jan; 99 (Pt 2): 318
34. Li J, Gross G, Osur S, et al. A comparison of commonly-prescribed doses of inhaled fluticasone propionate (FP) and inhaled triamcinolone acetonide (TAA) on HPA axis function. Am J Respir Crit Care Med 1998 Mar; 157 (3 Pt 2): A407
35. Tita J, LaForce C, Howland WC, et al. Use of 6-hr cosyntropin stimulation tests to evaluate potential effects of inhaled fluticasone propionate (FP), inhaled triamcinolone acetonide (TAA), placebo (PBO) and oral prednisone on HPA axis function [abstract]. Am J Respir Crit Care Med 1997; 155 (4 Pt 2): A355
36. Srebro SH, Rogenes PR, Edwards L, et al. Comparison of efficacy and HPA effects of fluticasone propionate versus flunisolide in patients with mild to moderate asthma [abtract]. Am J Respir Crit Care Med 1998 Mar; 157 (Suppl. Pt 2): 406
37. Leblanc P, Mink S, Keistinen T, et al. A comparison of fluticasone propionate 200 μg/day with beclomethasone dipropionate 400 μg/day) in adult asthma. Allergy 1994 May; 49: 380-5
38. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 1997 Jan; 52: 55-8
39. Falcoz C, Mackie AE, Moss J, et al. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler and the Diskus powder devices in asthmatic patients [abstract]. Br J Clin Pharmacol 1997 May; 43: 541-2
40. Meibohm B, Mollmann H, Wagner M, et al. The clinical pharmacology of fluticasone propionate. Rev Contemp Pharmacother 1998; 9: 535-49
41. Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids. Part 1 pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 1998; 102 (4 Pt 2): S36-51
42. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998; 101 (4 Pt 2): S440-6
43. Thorsson L, Dahlstrom K, Edsbacker S, et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997; 43: 155-61
44. Esmailpour N, Hogger P, Rabe KF, et al. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997; 10: 1496-9
45. Inhaled fluticasone propionate prescribing information. Research Triangle Park, NC, USA, Glaxo Wellcome Ltd. 1998
46. Falcoz C, Mackie AE, Moss J, et al. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler and the Diskus after repeat doses in healthy subjects and asthmatic patients [abstract no. 2041]. J Allergy Clin Immunol 1997; 99 (1 Pt 2): S505
47. Mackie AE, Ventresca GP, Fuller RW, et al. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996; 41: 539-42
48. Mackie A, Falcoz C, McDowall J, et al. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler (Rm) and tbe Diskus (Rm) powder devices in healthy subjects. Br J Clin Pharmacol 1997 May; 43: 540-1
49. Sheffer AL, Laforce C, Chervinsky P, et al. Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. J Fam Pract 1996 Apr; 42: 369-75
50. Wolfe JD, Selner JC, Mendelson LM. Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. Clin Ther 1996 Jul-Aug; 18: 635-46
51. Mahajan P, Okamoto LJ, Schaberg A. Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma. J Asthma 1997; 34 (3); 227-34
52. Galant SP, Lawrence M, Meltzer EO, et al. Fluticasone propionate compared with theophylline for mild-to-moderate asthma. Ann Allergy Asthma Immunol 1996 Aug; 77: 112-8
53. Pauli G, Aubert B, French SG. A comparison of inhaled fluticasone propionate with nedocromil in the treatment of moderate adult asthma. Eur J Clin Res 1995; 7: 45-56
54. Grison R, Pellegrino R, D'Amato G, et al. Comparison of inhaled fluticasone propionate 250 mcg bd and inhaled nedocromil sodium 4mg QDS both administered with inhaled or oral long acting bronchodilators over three month period in adult with unstable chronic asthma [abstract no. P1184]. Eur Respir J 1997 Sep; 10 Suppl. 25: 174s
55. Johnson MC, Matz J, Srebro S, et al. Greater improvement in asthma control with fluticasone propionate than with either zafirlukast or placebo. Chest 1998; 114 Suppl. 4: 296s
56. -1) administered by pressurized inhaler. Respir Med 1993; 87: 609-20
57. Rapheal GD, Baker JW, Chervinsky P, et al. Low dose fluticasone propionate (FP) is more effective than higher doses of beclomethasone dipropionate (BDP) in patients with mild to moderate asthma [abstract no. 24]. J Allergy Clin Immunol 1998 Jan; 101: S6
58. Miyamoto T, Takishima T, Makino S, et al. Clinical examination of fluticasone propionate dry powder - comparison between beclomethasone dipropionate inhaler in bronchial asthma [in Japanese]. Rinsho Iyaku 1994; 10 (2): 321-45
59. Basran G, Campbell M, Knox A, et al. An open study comparing equal doses of budesonide via Turbohaler with fluticasone propionate via Diskhaler in the treatment of adult asthmatic patients. Eur J Clin Res 1997; 9: 185-97
60. Burdon J, Bish R, Loder M, et al. A comparison of fluticasone propionate 250 μg BD via MDPT and budesonide 600 μg BD via Turbuhaler in adult asthmatics [abstract]. Aust N Z J Med 1997 Apr; 27: 247
61. Steinmetz K-O. Comparative efficacy and safety of fluticasone propionate MDI versus budesonide powder inhalation in the treatment of moderate asthma [in German]. Atemw Lungenkrkh 1997; 23 (12): 730-5
62. Venables TL, Addlestone MB, Smithers AJ, et al. A comparison of the efficacy and patient acceptability of once daily budesonide via Turbohaler and twice daily fluticasone propionate via disc-inhaler at an equal daily dose of 400 μg in adult asthmatics. Br J Clin Res 1996; 7: 15-32
63. Bergmann K-C. Controlled clinical trial of fluticasone propionate dry powder inhaler versus flunisolide metered dose inhaler in patients with mild to moderate asthma [in German]. Pneumologie 1997 Jan; 51: 27-32
64. Srebro SH, Weber HH, Rogenes PR, et al. Comparison of fluticasone propionate with flunisolide in patients with mild to moderate asthma [abstract no. 27]. J Allergy Clin Immunol 1998 Jan; 101 (1 Pt 2): S6-7
65. Trautmann M. Efficacy of fluticasone propionate (0.5 mg daily) and flunisolide (1.0 mg daily) in steroid-naive asthmatics [abstract]. Am J Respir Crit Care Med 1995; 151 (4 Pt 2): A275
66. Condemi JJ, Chervinsky P, Goldstein MF, et al. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. J Allergy Clin Immunol 1997 Oct; 100: 467-74
67. Gross GN, Wolfe JD, Noonan MJ, et al. Differential effects of inhaled corticosteroids: fluticasone propionate versus triamcinolone acetonide. American J Managed Care 1998; 4 (2): 233-44
68. Boulet LP, Robson R, Stepner N. Clinical equivalence of once vs twice daily administration of inhaled fluticasone propionate in the treatment of mild and moderate asthma [abstract]. Eur Respir J 1996 Sep: 9 Suppl. 23: 52s
69. Clifford D, Adelglass J, ZuWallack R, et al. Fluticasone propionate administered via the Diskus 500mcg once daily or 250mcg twice daily is safe and effective in adult patients with asthma [abstract]. Am J Respir Crit Care Med 1997; 155 (4 Pt 2): A349
70. Kerwin EM, Finn A, Jones R, et al. Once daily treatment of asthma with fluticasone propionate via Diskus: dose response results [abstract no. B37]. American Lung Association/American Thoracic Society 1997 International Conference 1997 May 16-21, San Francisco, CA: 27
71. Gross GN, Chervinsky P, Gillman S, et al. Low dose inhaled fluticasone propionate once or twice daily via the Diskus is safe and effective in inhaled steroid dependent patients with asthma [abstract no. B37]. American Lung Association/American Thoracic Society 1997 International Conference 1997 May 16-21, San Francisco, CA: 26
72. Selner J, Boltansky H, Chervinsky P, et al. Low dose inhaled fluticasone propionate administered once daily or twice daily via the Diskus is as safe and effective as beclomethasone dipropionate in steroid naive patients with asthma [abstract]. J Allergy Clin Immunol 1997 Jan; 99 Pt 2: 322
73. Britton MG, Carrillo T, Almeida J. Combined Serevent and fluticasone propionate (50/100 μg strength) BD via one Diskus (Accuhaler) inhaler compared with salmeterol 50 μg and fluticasone propionate 100 μg BD via two separate Diskus inhalers [abstract]. Am J Respir Crit Care Med 1998 Mar; 157 (Suppl. Pt 2): 415
74. Ringdal N, Chapman KR, Backer V, et al. Asthma control with salmeterol and fluticasone propionate (50/250 μg) given twice daily in a single combination Diskus (Accuhaler) inhaler compared to salmeterol 50 μg and fluticasone propionate 250 μg given twice daily via 2 separate Diskus inhalers [abstract no. P0330]. Eur Respir J 1998; 12 Suppl. 28: 36s
75. Gross G, Woodring A, Prillaman B, et al. Efficacy and safety of the salmeterol/fluticasone propionate (50/100 μg) dry powder combination inhaler in patients with asthma [abstract no. P1104]. Eur Respir J 1998; 12 Suppl. 28: 156s
76. Cook D, Srebro SH, Rogenes PR, et al. A comparison of the safety and efficacy of fluticasone, triamcinolone, and fluticasone plus salmeterol in patients with mild to moderate asthma [abstract]. Am J Respir Crit Care Med 1998 Mar; 157 Suppl. Pt 2: 416
77. Di Lorenzo G, Polverino M, Ferranti P, et al. Comparison of fluticasone propionate and beclomethasone dipropionate both in combination with salmeterol in patients with moderate asthma [abstract]. Am J Respir Crit Care Med 1997; 155 (4): A348
78. Edwards T, Gross G, Mitchell D, et al. The salmeterol xinafoate/fluticasone propionate dry powder combination product via Diskus inhaler improves asthma control compared to salmeterol xinafoate or fluticasone propionate dry powder alone [abstract]. Am J Respir Crit Care Med 1998 Mar; 157 (Suppl. Pt 2): 414
79. Ind PW, Dal Negro R, Fletcher CP, et al. Inhaled salmeterol and fluticasone propionate therapy in moderate adult asthma [abstract]. J. Eur Respir J 1997 Sep; 10 Suppl. 25: 1
80. Ind PW, Dal Negro R, Colman N, et al. Inhaled fluticasone propionate and salmeterol in moderate adult asthma I: lung function and symptoms. Am J Respir Crit Care Med 1998; 157 (3 Pt 2): A416
81. Ind PW, Dal Negro R, Colman N, et al. Inhaled fluticasone propionate and salmeterol in moderate adult asthma II: exacerhations. Am J Respir Crit Care Med 1998 Mar; 157 (3 Pt 2): A415
82. Kalberg CJ, Nelson H, Yancey S, et al. A comparison of added salmeterol versus increased-dose fluticasone in patients symptomatic on low-dose fluticasone [abstract]. J Allergy Clin Immunol 1998 Jan; 101 Suppl.: S6
83. Stricker W, Weinstein S, Chervinsky P, et al. Additive benefits of concurrent salmeterol and fluticasone propionate therapy in asthma [abstract]. J Allergy Clin Immunol 1997 Jan; 99 Pt 2: 319
84. Juniper EF, Guyatt GH, Ferrie PJ, et al. Measuring quality of life in asthma. Am Rev Respir Dis 1993; 147: 832-8
85. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: 81-7
86. Johansson G, McIvor RA, D'Ambrosio Purello F, et al. Salmeterol/fluticasone propionate combination dry powder inhaler (50/100 μg BID) is more effective than budesonide (400 μg BID) in mild to moderate asthma [abstract]. Eur Respir J 1998; 12 Suppl. 29: 20s
87. Bowers B, Cox F, Johnson M, et al. Patients receiving inhaled fluticasone propionate 88 mcg bid (FP) report greater improvements in quality of life versus patients receiving zafirlukast 20 mg bid (ZAF) [abstract]. Chest 1998; 114 Suppl. 4: 300s
88. Johannsou L-O. A comparison of once-daily of fluticasone propionate (FP) 200 μg and budesonide (BUD) 400 μg and twice-daily fluticasone propionate (FP) 100 μg. Am J Respir Crit Care Med 1998 Mar; 157 (3 Pt 2): A404
89. Wiessmann KJ, Trautmann M. Fluticasone propionate (500 mu daily) and flunisolide (1000 mu daily) in the treatment of steroid-naive patients with moderate asthma [abstract]. Eur Respir J 1994; 7 Suppl. 18: 383
90. Bateman ED, Brilton M, Carrillo J, et al. Salmeterol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin Drug Invest 1998 Sept 16: 193-201
91. Weersink EJM, van Zomeren EH, Koeter GH, et al. Treatment of nocturnal airway obstruction improves daytime cognitive performance in asthmatics. Am J Respir Crit Care Med 1997; 156: 1144-50
92. Reese PR, Mahajan P, Woodring A. Salmeterol/fluticasone propionate combination product improves quality of life in asthma patients [abstract no. P0325]. Eur Respir J 1998; 12 Suppl. 28: 35s
93. Mahajan P, Davis G, Field E. Asthma-specific quality of life improves following asthma treatment with fluticasone propionate powder 250mcg twice daily or 500mcg once daily [abstract]. Am J Respir Crit Care Med 1997; 155 (4 Pt 2): A349
94. Lundback B, Dahl R, De JM, et al. A comparison of fluticasone propionate when delivered by either the metered-dose inhaler or the Diskhaler inhaler in the treatment of mild-to-moderate asthma. Eur J Clin Res 1994; 5: 11-9
95. Pieters WR, Stallaert RALM, Prins J, et al. A study on the clinical equivalence and patient preference of fluticasone propionate 250 μg twice daily via the Diskus/Accuhaler inhaler or the Diskhaler inhaler in adult asthmatic patients. J Asthma 1998; 35 (4): 337-45
96. Mahajan P, Okamoto L. Patient satisfaction with the Diskhaler and the Diskus inhaler, a new multidose powder delivery system for the treatment of asthma. Clin Ther 1997 Sep-Oct; 19: 1126-34
97. Nielsen K, Okamoto L, Shah T. Importance of selected inhaler characteristics and acceptance of a new breath-actuated powder inhalation device. J Asthma 1997; 34 (3): 249-53
98. Schlaeppi M, Edwards K, Fuller RW, et al. Patient perception of the Diskus inhaler: a comparison with the Turbuhaler inhaler. Br J Clin Prat 1996; 50: 14-9
99. Backman R, Pickering CAC, Baumgarten C, et al. A comparison of fluticasone propionate via Diskus (Accuhaler) inhaler and budesonide via Turbuhaler inhaler in adult asthmatics [abstract]. J Allergy Clin Immunol 1996 Jan; 97 (Pt 3): 249
100. Booth P, Capsey L, Langdon C, et al. A comparison of the cost-effectiveness of alternative prophylactic therapies in the treatment of adult asthma. Br J Med Econ 1995; 8: 65-72
101. Steinmetz K-O, Volmer T, Traulmann M. Cost effectiveness of fluticasone and budesonide in patients with moderate asthma. Clin Drug Invest 1998 Aug; 16: 117-23
102. Venables TL, McConchic S, Follows RMA. A comparison of the cost-effectiveness of budesonide and fluticasone dry-powder devices in the management of adult asthma. Br J Med Econ 1996; 10: 315-23
103. Volmer T, Weber HH, Kielhorn A. Cost-effectiveness of fluticasone propionate and flunisolide in the treatment of moderate asthma [abstract]. Am J Respir Crit Care Med 1998 Mar; 157 (Suppl. Pt 2): 406
104. Volmer T, Wiessmann KJ, Kielhorn A. Fluticasone propionate vs flunisolide in the treatment of steroid-naive patients with moderate asthma: a cost effectiveness analysis of an open study [abstract]. Am J Respir Crit Care Med 1998 Mar; 157 (3 Pt 2); A408
105. Inhaled fluticasone propionate prescribing information. Glaxo Wellcome Ltd. Uxbridge, UK, 1998
106. Laitinen L, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993; 147: 697-704
107. Beasley R, Roche WR, Roberts JA, et al. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989; 139: 806-17
108. Kirby JG, Hargreave FE, Gleich GJ, et al. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis 1987; 136: 379-83
109. Trigg CJ, Manolitsas ND, Wang J, et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 1994; 150: 17-22
110. 2-agonist, terbutaline, with an inhaled corticosteroid, budesunide, in newly detected asthma. N Engl J Med 1991; 325: 388-92
111. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142: 832-6
112. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90: 32-42
113. Selroos O, Pictinalho A, Löfroos A-B, et al. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995; 108: 1228-34
114. Haahtela T, Järvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700-5
115. Blais L, Suissa S, Boivin J-F, et al. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma. Thorax 1998; 53: 1025-9
116. Jitulis DE, Meng Y-Y, Elashoff RM, et al. Preventive pharmacologic therapy among asthmatics: five years after publication of guidelines. Ann Allergy Asthma Immunol 1998; 81: 82-8
117. Kaur B, Anderson HR, Austin J, et al. Prevalence of asthma symptoms, diagnosis, aud treatment in 12-14 year old children across Great Britain (international study of asthma and allergies in childhood, ISAAC UK). BMJ 1998; 316: 118-24
118. Bousquet J, Knani J, Henry C, et al. Undertreatment in a non-selected population of adult patients with asthma. J Allergy Clin Immunol 1996 Sep; 98: 514-21
119. Lang DM, Sherman MS, Polansky M. Guidelines and realities of asthma management: the Philadelphia story. Arch Intern Med 1997 Jun 9; 157: 1193-200
120. Ferrante E, Muzzolon R, Fuso L, et al. Bronchial asthma: still an inadequately assessed and improperly treated disease. J Asthma 1904; 31: 117-21
121. Gaist D, Hallas J, Hansen N-CG, et al. Are young adults with asthma treated sufficiently with inhaled steroids? A population-based study of prescription data from 1991 and 1994. Br J Clin Pharmacol 1996; 41: 285-9
122. Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997; 277: 887-91
123. Van Ganse E, Hubloue I, Vincken W, et al. Actual use of inhaled corticosteroids and risk of hospitalisation: a case-control study. Eur J Clin Pharmacol 1997; 51: 449-54
124. Griffiths C, Naish J, Sturdy P, et al. Prescribing and hospital admissions for asthma in cast London. BMJ 1996; 312: 481-2